Excalipoint debuts with $68.7m to progress TCE pipeline [Yahoo! Finance]
NovaBridge Biosciences - American Depositary Shares (NBP)
Company Research
Source: Yahoo! Finance
engager (TCE) therapies in immunology and oncology as it emerges with $68.7m in seed funding under its wing. Excalipoint, which operates under a NewCo model, obtained the financing through an oversubscribed seed round, in which it secured $41m in funding from co-leading Chinese investors like Apricot Capital, HSG and Yuanbio Venture Capital, as well as contributions from four other companies. After becoming fully operational and progressing elements of its pipeline, Excalipoint raised a further $27.7m in an extension round supported by prominent investors Lilly Asia Ventures and Eisai Innovation. With this cash in hand, Excalipoint will progress its pipeline of TCE therapies, which includes six programmes spanning several solid tumour indications and immunological diseases. According to the company, its pipeline looks to address the common challenges associated with TCE therapies by turning ‘cold' tumours ‘hot', while addressing the tumour microenvironment. The jewel in the co
Show less
Read more
Impact Snapshot
Event Time:
NBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBP alerts
High impacting NovaBridge Biosciences - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
NBP
News
- I-Mab (NBP) had its "buy" rating reaffirmed by HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer [Yahoo! Finance]Yahoo! Finance
- NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric CancerGlobeNewswire
- Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD StudyPR Newswire
- NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript [Seeking Alpha]Seeking Alpha
NBP
Sec Filings
- 4/1/26 - Form 3
- 3/24/26 - Form 3
- 3/19/26 - Form 3
- NBP's page on the SEC website